<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913143</url>
  </required_header>
  <id_info>
    <org_study_id>PQ-110-003</org_study_id>
    <secondary_id>2018-003501-25</secondary_id>
    <nct_id>NCT03913143</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)</brief_title>
  <acronym>ILLUMINATE</acronym>
  <official_title>Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A&gt;G Mutation (p.Cys998X) in the CEP290 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProQR Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProQR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double-masked, randomized, controlled, multiple-dose study is to evaluate
      the efficacy, safety, tolerability and systemic exposure of sepofarsen (QR-110) administered
      via intravitreal injection in subjects with Leber's Congenital Amaurosis (LCA) due to the
      CEP290 p.Cys998X mutation after 24 months of treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this double-masked, randomized, controlled, multiple-dose study is to evaluate
      the efficacy, safety, tolerability and systemic exposure of sepofarsen (QR-110) administered
      via intravitreal injection in subjects with Leber's Congenital Amaurosis (LCA) due to the
      CEP290 p.Cys998X mutation after 24 months of treatment.

      At study start subjects will be randomized to one of 3 treatment groups with either active
      study drug or sham treatment.

      Sepofarsen (QR-110) will be administered via intravitreal (IVT) injection into the subject's
      treatment eye (the subject's worse eye).

      Subjects in the sham-procedure group will undergo a procedure that will closely mimic the
      active injection.

      After each dosing subjects will be assessed for safety and tolerability at follow up visits.

      After the first eye has been treated for at least 12 months, treatment of the contralateral
      eye and cross-over of subjects assigned to sham may be initiated based on assessment of
      benefit/risk (including review of data from all clinical trials), and with concurrence of the
      Medical Monitor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in BCVA after 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change in Best-corrected visual acuity (BCVA) relative to baseline after 12 months of treatment versus sham</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects ≥-0.3 LogMAR change in BCVA vs sham</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Percentage of subjects with baseline BCVA ≥ 1.7 Logarithm of the minimum angle of resolution (LogMAR) with ≥ 0.3 LogMAR change in BCVA in treated versus sham</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects &lt;1.7 Logmar with clinical meaningful improvement in mobility course score</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Percentage of subjects with baseline BCVA &lt; 1.7 LogMAR with a clinically meaningful improvement in mobility course score in treated versus sham</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BCVA between two QR-110 dose groups</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in BCVA relative to baseline in the Dose 1 QR-110 dose group versus the dose 2 QR-110 dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BCVA to baseline in pooled QR-110 subjects</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in BCVA in both QR-110 dose groups pooled relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mobility course score</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in mobility course score relative to baseline in the treatment eye versus sham</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mobility course score binocular vision</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in mobility course score binocular vision versus baseline versus sham</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in oculomotor instability from baseline</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Rate of change in oculomotor instability from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-field light sensitivity threshold (FST) testing for white light from baseline</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Full-field light sensitivity threshold (FST) testing for white light from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-field light sensitivity threshold (FST) testing for red light from baseline</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Full-field light sensitivity threshold (FST) testing for red light from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-field light sensitivity threshold (FST) testing for blue light from baseline</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Full-field light sensitivity threshold (FST) testing for blue light from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in photoreceptor inner/outer segment by OCT</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in photoreceptor inner segment/outer segment (inner segment [IS]/outer segment [OS]; ellipsoid zone [EZ] line) assessed by OCT relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported visual function via VFQ-25 (adults)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in patient reported visual function, as measured by the Visual Function Questionnaire-25 (VFQ-25) score for adult subjects relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported visual function via CVAQC (pediatrics)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in patient reported visual function, as measured by the Cardiff Visual Ability Questionnaire for Children (CVAQC) for pediatric subjects relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Patient Global Impressions of Severity (PGI-S)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in the patient-reported outcome (PRO) Patient Global Impressions of Severity (PGI-S)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Patient Global Impressions of Change (PGI-C)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in the PRO Patient Global Impressions of Change (PGI-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ERG</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Electroretinogram (ERG) via International Society for Clinical Electrophysiology of Vision [ISCEV] standard for full-field clinical ERG) relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ophthalmic examination findings</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Changes in ophthalmic examination findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of ocular AEs</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Severity of ocular AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of non-ocular AEs</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Frequency of non-ocular AEs</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leber Congenital Amaurosis 10</condition>
  <condition>Blindness</condition>
  <condition>Leber Congenital Amaurosis</condition>
  <condition>Vision Disorders</condition>
  <condition>Sensation Disorders</condition>
  <condition>Neurologic Manifestations</condition>
  <condition>Eye Diseases</condition>
  <condition>Eye Diseases, Hereditary</condition>
  <condition>Eye Disorders Congenital</condition>
  <condition>Retinal Disease</condition>
  <arm_group>
    <arm_group_label>Group 1: Dose 1 sepofarsen (QR-110)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Dose 2 sepofarsen (QR-110)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Intravitreal Injection (no experimental drug administered), at month 0, month 3 and every six months there after. After 12 months cross over to active study drug may be initiated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sepofarsen</intervention_name>
    <description>RNA antisense oligonucleotide for intravitreal injection</description>
    <arm_group_label>Group 1: Dose 1 sepofarsen (QR-110)</arm_group_label>
    <arm_group_label>Group 2: Dose 2 sepofarsen (QR-110)</arm_group_label>
    <other_name>QR-110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham intravitreal injection (no experimental drug administered)</description>
    <arm_group_label>Group 3: Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Male or female, ≥ 8 years of age at Screening with a clinical diagnosis of LCA and a
             molecular diagnosis of homozygosity or compound heterozygosity for the CEP290
             p.Cys998X mutation, based on genotyping analysis at Screening. Historic genotyping
             results from a certified laboratory are acceptable with Sponsor approval.

          -  BCVA greater or equal to Logarithm of the Minimum Angle of Resolution (LogMAR) +3.0,
             and equal or worse than LogMAR + 0.4 in the treatment eye.

          -  Detectable outer nuclear layer (ONL) in the area of the macula.

          -  An electroretinogram (ERG) result consistent with LCA. A historic ERG result may be
             acceptable for eligibility.

        Main Exclusion Criteria:

          -  Any contraindication to IVT injection according to the Investigator's clinical
             judgment and international guidelines (Avery 2014).

          -  Any ocular and/or general disease or condition that could compromise subject's safety
             or interfere with assessment of efficacy and safety, as determined by the
             Investigator.

          -  Prior receipt of intraocular surgery or IVT injection within 3 months prior to study
             start or planned intraocular surgery or procedure during the course of the study.

          -  Use of any investigational drug or device within 90 days or 5 half-lives of Day 1,
             whichever is longer, or plans to participate in another study of a drug or device
             during the PQ-110-003 study period.

          -  Any prior receipt of genetic therapy for LCA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ProQR Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>ProQR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ProQR Clinical Trials Manager</last_name>
    <phone>+31 (0)88 1667000</phone>
    <email>info@proqr.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami - Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Caldwell</last_name>
      <phone>305-482-5251</phone>
      <email>dcaldwell@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Byron Lam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Walshire</last_name>
      <phone>319-467-5183</phone>
      <email>EYE-ProQR@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mitch Martin</last_name>
      <phone>319-467-5182</phone>
      <email>EYE-ProQR@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Russell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maribel Rodriguez</last_name>
      <phone>212-305-9535</phone>
      <email>mr3208@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Brooks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute - Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-4197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Blackerby</last_name>
      <phone>503-494-0020</phone>
      <email>ordc@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Center for Advanced Retinal &amp; Ocular Therapeutics</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Pearson</last_name>
      <phone>215-662-6396</phone>
      <email>denise.pearson@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Tomas Aleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Olfson</last_name>
      <phone>713-798-4037</phone>
      <email>molfson@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Tahira Scholle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent (UZ)</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Leroy</last_name>
      <email>bart.leroy@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Bart Leroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children - SickKids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaishnavi Batmanabane</last_name>
      <phone>+1 416-813-7654</phone>
      <phone_ext>301511</phone_ext>
      <email>vaishnavi.batmanabane@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Elise Heon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - Centre for Innovative Medicine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Koenekoop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de maladies rares CHNO des Quinze Vingt</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothée Dagostinoz</last_name>
      <phone>+33 1 40 02 14 57</phone>
      <email>ddagostinoz@15-20.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle Audo</last_name>
      <phone>+33 1 53 46 25 42</phone>
      <email>isabelle.audo@inserm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Isabelle Audo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Dollfus</last_name>
      <phone>+33(0)3 88 11 67 53</phone>
      <email>Helene.DOLLFUS@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène Dollfus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig Universität - Department of Ophthalmology</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lyubomyr Lytvynchuk</last_name>
      <phone>+49-641-985-43803</phone>
      <email>lyubomyr.Lytvynchuk@augen.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Lyubomyr Lytvynchuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tuebingen - Inst. for Ophthalmic Research</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Rindtorff</last_name>
      <phone>+49 7071 29 87747</phone>
      <email>andrea.rindtorff@stz-eyetrial.de</email>
    </contact>
    <investigator>
      <last_name>Katarina Stingl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam University Medica Center - Locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Wezel</last_name>
      <phone>+31 205668618</phone>
      <email>m.wezel@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Camiel Boon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Buster-Franc</last_name>
      <phone>+31 243613212</phone>
      <email>trialcentrum.ohk@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Carel Hoyng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Het Oogziekenhuis Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 BH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marja Scheeres</last_name>
      <phone>+31 104023437</phone>
      <email>M.Scheeres@oogziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>L. Ingeborgh van den Born</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital - NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shamima Akther</last_name>
      <phone>+44 0207 253 3411</phone>
      <phone_ext>4246</phone_ext>
      <email>shamima.akther2@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Michel Michaelides</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.proqr.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LCA10</keyword>
  <keyword>CEP290</keyword>
  <keyword>p.Cys998X</keyword>
  <keyword>c.2991+1655A&gt;G</keyword>
  <keyword>Leber's Congenital Amaurosis</keyword>
  <keyword>Antisense oligonucleotide</keyword>
  <keyword>RNA therapy</keyword>
  <keyword>QR-110</keyword>
  <keyword>sepofarsen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Sensation Disorders</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
    <mesh_term>Eye Diseases, Hereditary</mesh_term>
    <mesh_term>Eye Abnormalities</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

